Per-Gunnar Karehill

Title: Per-Gunnar Karehill: Innovator in Pharmaceutical Science

Introduction

Per-Gunnar Karehill is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of extended release dosage forms. His work focuses on improving the efficacy and administration of medications.

Latest Patents

Karehill holds a patent for an oral pharmaceutical extended release dosage form. This invention involves an enteric coated pharmaceutical extended release dosage form of a H, K-ATPase inhibitor. The formulation provides an extended plasma concentration profile, which is achieved through a pharmaceutical composition that includes a core material of a hydrophilic or hydrophobic matrix, along with the H, K-ATPase inhibitor and optionally pharmaceutically acceptable excipients. This innovative dosage form can be administered once daily, enhancing patient compliance and therapeutic outcomes.

Career Highlights

Karehill is associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to contribute to the development of advanced pharmaceutical formulations that address critical health needs. His expertise in pharmaceutical sciences has positioned him as a valuable asset in the industry.

Collaborations

Karehill has worked alongside Per Johan Lundberg, furthering research and development in the pharmaceutical sector. Their collaboration has likely led to advancements in drug formulation and delivery systems.

Conclusion

Per-Gunnar Karehill's contributions to pharmaceutical innovations, particularly in extended release dosage forms, highlight his role as a key inventor in the field. His work continues to impact the way medications are formulated and administered, ultimately benefiting patient care.